https://news.ketelle.co.uk/entities/pfizer Stories involving Pfizer, told neutrally, with how each side covers them. en-gb https://news.ketelle.co.uk/stories/vaxcyte-pneumococcal-vaccine-meets-primary-endpoints-in-phase-3-trial https://news.ketelle.co.uk/stories/vaxcyte-pneumococcal-vaccine-meets-primary-endpoints-in-phase-3-trial Mon, 05 Oct 2026 13:51:37 +0100 Health Vaxcyte said its 31-valent pneumococcal vaccine VAX-31 hit the primary endpoints in the Phase 3 OPUS-1 trial in adults, positioning it against Pfizer's Prevnar and Merck's Capvaxive. (2 outlets: 0 left · 1 centre · 1 right)